Literature DB >> 3980311

Primaxin in the treatment of acute bacterial pneumonia in adults.

R J Gebhart, R J Duma, P M Patterson, J W Bagett, D S Williams.   

Abstract

Imipenem (N-Formimidoyl thienamycin) (MK-0787) is a new beta-lactam carbapenem antibiotic. When it is combined with the renal dipeptidase inhibitor cilastatin (MK-0791) the combination is known as primaxin. In this study 28 adult patients (24 males and 4 females) with acute bacterial pneumonia were treated with primaxin. Twenty-one patients were evaluable and 20 (95%) were clinically cured of their pneumonia. Bacteriological cures were demonstrated in 84% of the cases. One patient with a susceptible Pseudomonas aeruginosa failed. Major complications or toxic reactions included antibiotic associated diarrhoea in one patient; hypotension in one patient; increased grand mal seizures in one patient and elevated liver function studies in one patient. Results of this study suggest that primaxin will be useful in the treatment of a variety of serious Gram-positive and Gram-negative pneumonias. The true incidence of possible toxic reactions with this drug is not known at this time and awaits further experience.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3980311     DOI: 10.1093/jac/15.2.233

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Comparative in vitro activity of imipenem against Haemophilus influenzae and Haemophilus parainfluenzae.

Authors:  A T Cerami; D L Shungu
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

3.  Animal model for evaluating the convulsive liability of beta-lactam antibiotics.

Authors:  P D Williams; D B Bennett; C R Comereski
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.